Related Experiment Video
Updated: Jun 27, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
A pan-HER approach for cancer therapy: background, current status and future development
Zhongdong Huang1, Cathleen Brdlik, Pei Jin
1Receptor BioLogix, Inc., Palo Alto, CA 94303, USA.
Expert Opinion on Biological Therapy
|December 10, 2008
Summary
A new therapy targets multiple human EGF receptor (HER) family members and ligands to improve cancer treatment. RB200, a bispecific ligand trap, offers a novel approach to combatting HER-driven malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- The human EGF receptor (HER) family and its ligands drive cancer aggressiveness.
- Current HER-targeted therapies (mAbs, TKIs) have limitations due to specificity issues.
- There is a clinical need for therapeutics targeting multiple HER family members and ligands.
Purpose of the Study:
- To summarize mechanisms of action for HER-targeted therapies.
- To analyze tumor resistance patterns against current anti-HER treatments.
- To introduce a novel pan-HER ligand sequestering agent for cancer therapy.
Main Methods:
- Review of therapeutic mechanisms.
- Analysis of tumor resistance to existing anti-HER agents.
- Introduction of a novel bispecific ligand binding trap.
Main Results:
- Current single-target agents have limitations in specificity and efficacy.
- Tumor resistance mechanisms necessitate broader therapeutic strategies.
- A novel pan-HER therapy has been developed.
Conclusions:
- RB200 is a bispecific (EGFR/HER3) ligand binding trap.
- RB200 addresses the need for a pan-HER therapy in human cancer.
- This approach offers potential for improved cancer treatment outcomes.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...